Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMei Yun Keen_US
dc.contributor.authorJan Tacken_US
dc.contributor.authorEamonn M.M. Quigleyen_US
dc.contributor.authorDuowu Zouen_US
dc.contributor.authorSuck Chei Choien_US
dc.contributor.authorSomchai Leelakusolvongen_US
dc.contributor.authorAndy Liuen_US
dc.contributor.authorJin Yong Kimen_US
dc.contributor.otherPeking Union Medical Collegeen_US
dc.contributor.otherKU Leuvenen_US
dc.contributor.otherMethodist Hospital Houstonen_US
dc.contributor.otherSecond Military Medical Universityen_US
dc.contributor.otherWonkwang Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherJanssen Research and Developmenten_US
dc.contributor.otherJanssen Asia-Pacificen_US
dc.identifier.citationJournal of Neurogastroenterology and Motility. Vol.20, No.4 (2014), 458-468en_US
dc.description.abstract© 2014 The Korean Society of Neurogastroenterology and Motility. Background/Aims: To compare the efficacy and safety of prucalopride, a novel selective high-affinity 5-hydroxytryptamine type 4 receptor agonist, versus placebo, in Asian and non-Asian women with chronic constipation (CC). Methods: Data of patients with CC, receiving once-daily prucalopride 2-mg or placebo for 12-weeks, were pooled from 4 double-blind, randomized, phase-III trials (NCT00488137, NCT00483886, NCT00485940 and NCT01116206). The efficacy endpoints were: average of ≥ 3 spontaneous complete bowel movements (SCBMs)/week; average increases of ≥ 1 SCBMs/week; and change from baseline in each CC-associated symptom scores (bloating, abdominal pain, hard stool and straining). Results: Overall, 1,596 women (Asian [26.6%], non-Asian [73.4%]) were included in this analysis. Significantly more patients in the prucalopride group versus placebo experienced an average of ≥ 3 SCBMs/week in Asian (34% vs. 11%, P < 0.001) and non-Asian (24.6% vs. 10.6%, P < 0.001) subgroups. The number of patients reporting an increase of ≥ 1 SCBMs/week from baseline was significantly higher in the prucalopride group versus placebo among both Asian (57.4% vs. 28.3%, P < 0.001) and non-Asian (45.3% vs. 24.0%, P < 0.001) subgroups. The difference between the subgroups was not statistically significant. Prucalopride significantly reduced the symptom scores for bloating, hard stool, and straining in both subgroups. Conclusions: Prucalopride 2-mg once-daily treatment over 12-weeks was more efficacious than placebo in promoting SCBMs and improvement of CC-associated symptoms in Asian and non-Asian women, and was found to be safe and well-tolerated. There were numeric differences between Asian and non-Asian patients on efficacy and treatment emergent adverse events, which may be partially due to the overlap with functional gastrointestinal disorders in non-Asian patients.en_US
dc.rightsMahidol Universityen_US
dc.titleEffect of prucalopride in the treatment of chronic constipation in Asian and non-Asian women: A pooled analysis of 4 randomized, placebo-controlled studiesen_US
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.